Overview

• Presented at the ESCRS Congress in Copenhagen, the Buenos Aires team reported rapid, dose-dependent improvements averaging 3.45 Jaeger lines one hour after first administration.
• The regimen combines pilocarpine with diclofenac, was dosed twice daily with an optional third dose, and showed median durability of 434 days with follow-up extending to two years.
• By concentration, 99% of patients on 1% pilocarpine read two or more extra lines, while 69% on 2% and 84% on 3% read three or more extra lines.
• Adverse effects were mostly mild—temporary dim vision (32%), instillation irritation (3.7%), and headache (3.8%)—with no treatment discontinuations and no increases in intraocular pressure or retinal detachments reported.
• Independent experts noted potential risks with long-term pilocarpine and topical NSAIDs and called for broader, long-term, multi-centre trials to confirm safety, rare-event risks, and generalisability.